{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC).","groups":[{"description":"Idelalisib 150 mg tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"OG001","title":"Placebo + Rituximab"}],"populationDescription":"Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.","reportingStatus":"POSTED","title":"Progression Free Survival","type":"PRIMARY"}